Monolitum Flas 15 mg & 30 mg ODT - PPI - Rx
Product Description
Laboratorios Salvat, S.A.
-
ES -
2016On CPHI since
-
4Certificates
-
250 - 499Employees
Company types
Primary activities
.jpg)
Categories
Specifications
Laboratorios Salvat, S.A.
-
ES
-
2016On CPHI since
-
4Certificates
-
250 - 499Employees
Company types
Primary activities
More Products from Laboratorios Salvat, S.A. (21)
-
Product Relive® - Day & Night eye drops - MD
RELIVE® DRY EYE - 8 Hours of Dry Eye Relief
RELIVE® NIGHT - 12 Hours of Long-lasting Dry Eye Relief • Preservative-Free • Phosphate-Free • Single-dose vials, very Convenient format -
Product Cetraxal® Plus 3mg/ml + 0.25 mg/ml - AOE & AOMT - Otic solution Rx
Unique combination "ciprofloxacin 3 mg + Fluocinolone 0.25 mg" topical solution
Indication: Acute otitis externa and acute otitis media with perforated eardrums in adults and pediatric patients.
Dosage regimen: B.I.D x 7 days
Presentation of multi-dose 10 ml and unit dose vials (14... -
Product Ekzem® 0.25 mg/ml - Otic eczema - single-dose vials - otic solution Rx
Fluocinolone acetonide, topical solution. Ekzem is indicated for the treatment of otic eczema in adults. Demonstrated efficacy and safety in clinical studies
Available in unit dose vials of 0.4 ml each. (30 vials x box) -
Product Cristalmina® - Antiseptic - OTC
Chlorhexidine digluconate 1% Cristalmina®, offers a quick action and long-lasting effect.
Cristalmina®, the antiseptic leader in the Spanish market, is the most complete, for the whole family
Indication: Minor skin wounds and burns, even for the umbilical cord in newborns. -
Product Cetraxal® Otico 2mg/ml - AOE - Otic solution Rx
Ciprofloxacin 3 mg, topical solution.
Indication: AOE
Dosage: B.I.D x 7 days.
Presentation: Available in multidose 10ml and unit dose vials (15 vials). -
Product Cetraflux 3 mg/ml - Eye infection - single-dose vials eye drops - Rx
Cetraflux 3 mg/ml eye drop solution is indicated for the local treatment of the following infections caused by strains sensitive to ciprofloxacin, in adults, neonates (0-27 days), infants (aged 28 days to 23 months), children (aged 2-11 years), adolescents (aged 12-16 years). Available in single dose conta... -
Product Urosens range - Urinary infections - FS
"The most complete range for each type of cystitis"
Urosens: MAINTENANCE in occasional urinary infections.
Urosens forte: ADJUVANT in urinary infectionsUrosens mannose: MAINTENANCE & ADJUVANT in urinary infections, very recurrent urinary infection -
Product Nurane retina - AMD - FS
A sufficient dietary intake of the nutrients contained in Nurane Retina, supplemented when necessary, aids the correct functioning of the retina. Lutein and zeaxanthin are two carotenoids with antioxidant properties which help protect our bodies from attack by free radicals. They have the following functio... -
Product Nutira range - Lactose intolerance - FS
Enables better digestion of dairy products. It helps break down lactose into its two constitutive elements (galactose and glucose) and prevents intestinal symptoms related to lactose intolerance (pain, abdominal swelling, meteorism and diarrhoea) from appearing after the consumption of any dairy product, p... -
Product Malacur
Dihydroartemisinin. Piperaquine Phosphate. Malaria
-
Product Tebarat® 0.5ml/ml - Allergic conjunctivities - single-dose vials eye drops - Rx
Tebarat® is azelastine 0.05% is indicated for the prevention and the treatment of allergic conjunctivitis. Eye drp presented in single-dose vials, preservative-free.
-
Product SVT-15473 - Inflammation and pain after ocular surgery - Clobetasol 0.05% nanoemulsion Rx
SVT-15473 is the first strongest ophthalmic corticosteroid formulated in nanoemulsion (nanodroplets below ~30nm), using IMPACT-SVT®, a patented drug delivery technology, and in single-dose vials, using Blow-Fill-Seal technology packaging.
SVT-15473 has&nbs...
Laboratorios Salvat, S.A. resources (11)
-
News Laboratorios Salvat inicia un estudio pediátrico pionero en Europa con su fármaco innovador SVT-15473, para el tratamiento de la inflamación y dolor tras la cirugía ocular
- Los ensayos clínicos fase III realizados en adultos confirman la eficacia y el excelente perfil de seguridad de SVT-15473 clobetasol oftálmico, formulado con IMPACT-SVT® tecnología patentada de nanoemulsiones, para el tratamiento de la inflamación y el dolor después de una cirugía ocular.
- Es el primer estudio clínico que se realiza en paciente pediátrico con un corticoide tópico oftálmico en toda Europa.
- Con el nuevo estudio que se inicia ahora y que se llevará a cabo en seis hospitales españoles se espera demostrar también su seguridad en pacientes pediátricos de 0 a 3 años.
- Con este proyecto, que ha supuesto una inversión global de más de 20 millones de euros, Laboratorios Salvat da un paso más en su estrategia de afianzarse como un actor clave en el área de oftalmología a nivel internacional.
-
Video SVT-15473 + IMPACT-SVT® Nanoemulsion technology
Salvat has developed IMPACT-SVT®, a patented nanoemulsion drug delivery technology that improves drug mucus penetration and bio-adhesion, providing excellent ocular comfort.
IMPACT-SVT® made it possible to develop SVT-15473, using the strongest corticosteroid in the global market.
-
News Salvat Laboratories presented Phase III clinical trials results of Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting
Salvat Laboratories, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans.
-
Brochure Cristalmina® - Topical antiseptic
Cristalmina®, offers a quick action and long-lasting effect.
Indicated in the disinfection of burns and superficial wounds; even for the umbilical cord in newborns.
Chlorhexidine is the antiseptic of reference, widely recommended in different clinical guidelines.
Licensing opportunity: Cristalmina®, 10 mg/ml, cutaneous spray solution in 25 ml & 125 ml.
-
News Salvat Laboratory Submits Application to the US FDA for Approval of Clotrimazole, a Pioneering Drug for the Treatment of Otomycosis
- The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa.
- Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international level.
-
Brochure CDMO Services
Salvat offers an integrated End-to-Endsolution, to ensure your project’s commercial success. We offer the latest technologies withoptimum quality, flexibility andoperational excellence. With over 65years of experience, we can provide theservices and solutions that make ourpartners successful. -
News Salvat Laboratories announces submission of New Drug Application to the US FDA for Clobetasol Nanoemulsion
Salvat Laboratories, the international company, which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. -
Brochure Licensing product list
Sharing a commitmentto patients worldwide
LICENSING-OUT our products focuson Ophthalmology, Otorhinolaryngology,Gastroenterology & Consumer Health Care.
LICENSING-IN products for the Spanish,Portuguese, African and Central Americamarkets. Our areas of interest are in Rx productsat Ophthalmology, Otorhinolaryngology andGastroenterology. -
News Salvat’s Pharmaloop Invests 65 million Euros in Its New Sterile Liquids Plant, located in Alcalá de Henares
The new 8,500 m² plant is equipped with the most advanced technology, highest quality standards and the capacity to produce more than 350 million units of sterile formulations per year. -
Video New manufacturing capabilities - Sterile Liquids
Over 60 years of experience in the pharmaceutical industry Salvat offers complete CDMO services.Expertise in Blow-Fill-Seal technology, single-dose vials
Manufacturing sites located in Barcelona, Madrid & Miami -
News Salvat completes Phase III clinical trials of its new ophthalmic corticosteroid nanoemulsion
The aim of these trials, which began in 2020, is to prove the efficacy of this innovative drug in treating ocular inflammation and pain after cataract surgery. For the first time in the world, this new product will use nanoparticles applied to the eye in order to help the drug’s absorption and application.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance